MSAC Secretariat publishes agenda for November 2023 MSAC meeting

MSAC

26 July 2023 - The MSAC Secretariat has published a list of applications scheduled to be considered by the MSAC on 23 -24 November 2023.

The agenda currently has 10 items. Applications of note include:

  • 1690.1 – Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T cell to treat refractory or relapsed multiple myeloma
  • 1716 – Germline BRCA mutation test to detect BRCA1 or BRCA2 mutations in patients with HER2- negative high risk early breast cancer to determine eligibility for PBS-listed olaparib treatment
  • 1723.1 - Brexucabtagene autoleucel for adult relapsed or refractory B-precursor acute lymphoblastic leukaemia

Read MSAC agenda

Michael Wonder

Posted by:

Michael Wonder